

---

## DOSIsoft Launches DOSIsoft Theranostics, a Dedicated Entity to Accelerate Software Innovation for Personalized Nuclear Medicine and Theranostics

Ahead of SNMMI 2026, [DOSIsoft](#), a leading provider of dosimetry software for radiation oncology and nuclear medicine, today announced the launch of **DOSIsoft Theranostics**, a dedicated entity focused on developing **theranostics software** for broader **routine clinical adoption**.

As an **independent player fully dedicated to theranostics**, DOSIsoft Theranostics is uniquely positioned to serve the broader clinical and industrial ecosystem as a neutral, trusted software partner, with the **strategic autonomy to pursue its own innovation, partnerships, and long-term investments**.

By combining diagnostics with targeted therapies to enable truly personalized treatment, theranostics is entering a new phase of clinical and industrial expansion. Building on more than **two decades of DOSIsoft expertise**, DOSIsoft Theranostics will accelerate innovation in software solutions supporting **radiopharmaceutical therapies** and the evolution of nuclear medicine toward more **quantitative imaging, AI-driven workflows, and personalized care**.

Focused on routine clinical use, the organization is built for a field where **individualized patient therapy monitoring** increasingly spans **multiple imaging modalities, hospital departments, successive treatment cycles, and combined therapeutic approaches**. Cutting-edge software tools and dedicated scientific expertise will also help advance research and clinical innovation.

**At the core of DOSIsoft Theranostics is PLANET®**, DOSIsoft's flagship software platform for theranostics. Rooted in DOSIsoft's heritage in external beam radiation therapy treatment planning, PLANET® has evolved into a comprehensive platform with **advanced voxel-based multi-radionuclide dosimetry capabilities** and **full multimodality DICOM interoperability**. **FDA 510(k) cleared and CE marked**, PLANET® is deployed in **leading hospitals and academic centers worldwide**, with a **vendor-neutral architecture** that gives clinicians the flexibility to support **diverse clinical workflows and therapeutic strategies**.

*"Creating a **dedicated theranostics organization** reflects DOSIsoft's **long-term commitment** to this rapidly expanding field. It gives DOSIsoft Theranostics the **strategic focus and agility** to accelerate **innovation, foster new partnerships, and expand theranostics applications worldwide**." said Marc Uszynski, CEO of DOSIsoft.*

DOSIsoft Theranostics will be present at [SNMMI 2026 \(#1358\)](#).

### About DOSIsoft

Founded in 2002, DOSIsoft is a market leader in dosimetry software for radiation oncology and nuclear medicine, dedicated to improving cancer treatment quality and patient safety. With more than 1,000 installations across 800+ hospital centers in 80 countries, DOSIsoft provides advanced solutions for radiation therapy quality assurance, theranostics, and personalized dosimetry. A spin-off from Gustave Roussy and Institut Curie, DOSIsoft continues to innovate through close collaboration with leading cancer centers worldwide. DOSIsoft is a contributing partner of the European Thera4Care project (Theranostics Ecosystem for Personalized Care). Press contact: [xiaolu.chen@dosisoft.com](mailto:xiaolu.chen@dosisoft.com)